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Abstract:  Some quinone oxidoreductases exhibit negative cooperativity towards inhibitors. In human NQO1, this is mediated by flexibility around 
glycine-150.  Here we investigated the eubacterial orthologue, Modulator of Drug Activity B (MdaB) to determine if it shows cooperativty towards 
substrates or inhibitors and to investigate molecular recognition of the inhibitor, dicoumarol.  Like human NQO1, MdaB did not show cooperativity 
towards substrates.  However, unlike NQO1, it was only weakly inhibited by dicoumarol.  Alanine-127 in MdaB is the structurally equivalent residue to Gly-
150 in human NQO1. With the intention of increasing protein flexibility in MdaB, this alanine was altered to glycine. This change did not increase 
cooperativity towards inhibitors or NADPH. Based on structural alignment to NQO1 in complex with dicoumarol, an asparagine in the active site was 
changed to alanine to reduce steric hindrance. This change resulted in enhanced inhibition by dicoumarol, but the inhibition was not cooperative. Both 
changes were then introduced simultaneously. However, the additional increase in flexibility afforded by the change to glycine did not enable negative 
cooperativity towards dicoumarol.  These results have implications for the evolution of quinone oxidoreductases and their potential use as biocatalytsts. 
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Introduction 
Quinone oxidoreductases catalyse the two electron reduction of quinones 
at the expense of NADH or NADPH. The best characterized example is 
mammalian NAD(P)H quinone oxidoreductase 1 (NQO1, DT-diaphorase, 
EC 1.6.5.2) [1-3]. This enzyme has received considerable attention due to its 
potential as a cancer chemotherapy target, its postulated role in vitamin K 
metabolism and its interactions with cell signaling molecules such as p53 
[4]. Considerably less is known about quinone oxidoreductases from 
eubacteria. However, organisms from this domain often express several 
enzymes in this class. These include the nitroreductase enzymes (e.g. 
NemA, NfsA, NfsB, YdjA) and NQO1-like enzymes such as MdaB [5-10]. 
MdaB reduces quinones by the transfer of two electrons; therefore like 
NQO1 it has a postulated role in their detoxification. In Escherichia coli, the 
expression of MdaB is increased in the presence of menadione [11]. MdaB is 
proposed to work in tandem with a quinol monoxygenase (QuMo), 
forming a quinone redox cycle which enables E. coli to maintain an 
intracellular store of menadione (required for anaerobic growth) without 
the formation of semiquinones [12]. MdaB confers resistance to the 
antibiotics adriamycin, etoposide and DMP840 while QuMo confers 
resistance to adriamycin and tetracycline; these molecules are structurally 
similar to napthoquinones which point to a role in the cycling of these 
molecules until they can be conjugated [11].  There is also industrial interest 
in broad specificity oxidoreductase enzymes [13].  MdaB has potential since 
it is relatively stable and has an accommodating active site. 
Mammalian NQO1 and bacterial MdaB both have a tightly bound FAD 
cofactor [11, 14]; in contrast the nitroreductases and Lot6p proteins from 
budding yeasts use FMN [7-9, 15-17].  In both groups, the flavin cofactor plays 
a key role in catalysis, accepting electrons from NADH or NADPH in the 
first step of the reaction.  The oxidised NAD(P)+ then exits the active site 
and is replaced by the second substrate which is then reduced by the flavin 
cofactor [14].  MdaB reduces quinones by the transfer of two electrons 
suggesting that it is involved in their detoxification [18]. MdaB is a dimer 
with a classic flavodoxin fold. Each monomer has a large catalytic domain 
which aligns well with human and rat NQO1 [11].  
Human NAD(P)H quinone oxidoreductase 1 (NQO1), human NRH quinone 
oxidoreductase 2 (NQO2) and budding yeast Lot6p all exhibit negative 
cooperativity towards inhibitors such as dicoumarol and resveratrol [19-22]. 
Negative cooperativity is a decrease in affinity when sequential molecules 
of ligand bind [23, 24]. Binding of the first molecule causes a conformational 
change which is propagated through the protein and causes the effect 
elsewhere. Cooperativity, like catalysis, is therefore inextricably linked to 
protein motion and flexibility [24]. In human NQO1, glycine 150 has been 
identified as pivotal to the mechanism and a change from glycine to the 
more conformationally restricting residue serine at this position, largely 
abolished negative cooperativity [25].  
MdaB was structurally aligned to human NQO1 (PDB 2F1O [26]) and the 
equivalent residue to the pivotal glycine in NQO1 was identified as Ala-127 
in MdaB. To investigate whether, or not, negative cooperativity towards 
inhibitors could be introduced into MdaB, this alanine was changed to 
glycine in order to increase conformational freedom and flexibility at this 
position [27]. Dicoumarol inhibits NQO1 by binding in its active site; it π-
stacks with the isoalloxazine ring system of the FAD cofactor [26]. Since 
dicoumarol is a poor inhibitor of the oxidoreductase activity of MdaB, 
structural alignment with NQO1 in complex with dicoumarol (PDB: 2F1O 
[26]) was used to determine possible reasons why dicoumarol did not 
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favourably bind in the active site of MdaB. The alignment showed an 
asparagine residue in MdaB which may sterically hinder dicoumarol by 
protrusion into its potential binding pocket, preventing its optimum 
orientation. In particular, it was predicted to disrupt the potential for π-
stacking with FAD (Fig. 1). To reduce this steric hindrance, asparagine was 
changed to alanine with a view to facilitate dicoumarol binding and 
therefore enhance its inhibition of MdaB. 
Figure 1. Alignment of human NQO1 (PDB 2F1O [26]) with MdaB (PDB 
2B3D [11]) showing the protrusion of asparagine 126 (cyan) in MdaB into the 
dicoumarol (red) binding site in NQO1.  The position of the FAD cofactor in 
NQO1 and MdaB are shown in yellow and orange respectively. 
 
Results and Discussion 
The wild-type and variant forms of MdaB could be expressed in, and 
purified from, E. coli and, as expected, all dimerised as indicted by 
chemical crosslinking (data not shown).  
Wild-type MdaB exhibited monophasic thermal denaturation with a 
“melting temperature” (Tm) of 61.8±0.5 °C. All variant enzymes also 
exhibited monophasic melting (Supplementary Fig. S1). The change from 
alanine to glycine at position 127 destabilised the enzyme while the 
change from asparagine to alanine at position 126 was stabilising 
(Tm=53.4±0.1 °C and 63.5±0.0 °C respectively). The simultaneous change 
at both positions was, overall, destabilising, but to a lesser extent than the 
destabilising effect of the single change from alanine to glycine 
(Tm=56.5±0.0 °C; Supplementary Fig. S1). Residue 127, while close to the 
enzyme’s surface, is mostly buried. Examination of a space-filling model 
shows that it is likely to have access to solvent (data not shown). The 
effect of glycine relative to alanine for a solvent-exposed internal residue 
is likely to be destabilising because (i) the amount of buried hydrophobic 
surface area is less, (ii) it makes fewer van der Waals contacts and (iii) it 
loses more entropy on folding [28].  Residue 126 is positioned in a loop just 
before a small helix, protruding into the active site close to FAD and is 
partially solvent exposed.  Asparagine relative to alanine at this position is 
likely to be destabilising as it may hydrogen bond to the backbone in an 
unfolded states and there would be a reduction in conformational freedom 
and of the solvation of the asparagine. The destabilisation caused by Ala-
127 to Gly was presumably greater than the stability afforded by the 
change form Asn-126 to Ala explaining a net destabilisation of the double 
variant.  
Wild-type MdaB was active with NADPH as an electron donor and DCPIP 
as an electron acceptor (Fig 2); there was no detectable activity with 
NADH as electron donor (data not shown). Variants, p.A127G, p.N126A 
and p. N126A/A127G are active with NADPH as an electron donor and 
DCPIP as an electron acceptor. The kcat,app/Km,app value for p.A127G was 
greater than that for the wild-type enzyme (Table 1; Fig. 2) indicating that 
the change from alanine to glycine caused an increase in the enzyme’s 
activity with these substrates. The kcat,app/Km,app values for the p.N126A and 
p.N126A/A127G variants were lower than that for the wild-type enzyme 
(Table 1; Fig. 2). Wild-type MdaB does not exhibit negative cooperativity 
towards NADPH h=1.05±0.03. None of the changes to the enzyme 
affected cooperativity towards the electron donor as the values of h for 
each variant enzyme were close to 1 (Table 1; Fig. 2).  
The ligands nicotinamide, NADP+ and dicoumarol stabilised the WT 
enzyme towards thermal denaturation and this stabilisation was 
concentration-dependent (Fig. 3; Supplementary Fig. S2; Table 1). 
Hyperbolic behaviour was observed for nicotinamide but not for 
dicoumarol or for NADP+ at the maximum concentrations possible under 
the experimental conditions used. The curve for dicoumarol was almost 
linear. This indicates that the binding of dicoumarol is not exclusively in 
the active site of the WT enzyme or that the concentration range used was 
much lower than the KD,app value.  
The wild-type oxidoreductase activity was inhibited in a concentration-
dependent manner by nicotinamide and NADP+; dicoumarol (100 µM) did 
not inhibit the oxidoreductase activity.  Previously it was reported the 
inhibition of a bacterial oxidoreductase by dicoumarol with a competitive 
inhibition constant of 0.22 µM [29]. However, the authors reported the 
cofactor of this oxidoreductase to be FMN; the crystal structure of MdaB 
shows its cofactor to be FAD [11]. Therefore, although the authors drew a 
parallel between this enzyme and rat NQO1 it is not likely to be MdaB. The 
type of inhibition observed was mixed for NADP+ and nicotinamide. 
Negative cooperativity was observed towards NADP+, h =0.74 ±0.07; slight 
positive cooperativity was observed towards nicotinamide, h =1.20 ±0.12 
(Table 1; Fig. 3). The occurrence of both positive and negative 
cooperativity towards different ligands has been observed in other 
enzymes such as CTP synthetase and glyceraldehyde 3-phosphate 
dehydrogenase [30, 31]. Nicotinamide is a structural component of NADPH 
and NADP+ yet it induces slight positive cooperativity. The contrasting 
behaviour of NADP+ and NADPH is the most surprising since their only 
difference is that NADPH is the reduced form. The nature of the ping-pong 
mechanism provides an explanation; NADPH binds in the active site and 
donates two electrons to FAD and leaves the active site as the oxidised 
form. MdaB therefore undergoes conformational changes to facilitate the 
binding and release of the electron donor and since the binding of NADP+ 
is overall unfavourable as it is released from the active site, this infers that 
there are subtle differences in its binding mode compared to that for 
NADPH. These would allow NADP+ to induce negative cooperativity 
through a different binding mode than that of NADPH which does not 
induce cooperativity. The cooperativity towards NADP+ and nicotinamide 
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could also result from the effects of binding to different sites on the 
enzyme as indicated by mixed inhibition. 
The p.A127G variant was also stabilised towards thermal denaturation by 
dicoumarol and the relationship was saturating. Nicotinamide destabilised 
this variant and NADP+ had no effect (Table 1; Fig. 3; Supplementary Fig. 
S2). Favourable binding of a ligand to a partially unfolded protein can 
manifest as a destabilisation of the protein [32].  
The oxidoreductase activity of the p.A127G variant was also inhibited by 
these ligands in a concentration-dependent manner (Table 1; Fig. 2). The 
change from alanine to glycine did not affect the cooperativity towards 
NADP+. There was however, a slight increase in the value of h for 
nicotinamide to 1.40 ±0.12 (Table 1; Fig. 2). This indicates that alanine at 
position 127 may be involved in the cooperative effects induced by 
nicotinamide. It is likely that the alanine residue either contacts the 
nicotinamide directly or contacts the residues which interact first with the 
ligand. Moreover, since it is positioned in a loop at the end of a helical 
arrangement linking the two active sites, it is feasible that it is involved in 
the communication between them. This could occur by large scale 
backbone motion of the pathway and/or conformational changes of its 
residues and/or changes in dynamics. 
The p.N126A variant was stabilised towards thermal denaturation by 
dicoumarol (Table 1; Fig. 3; Supplementary Fig. S2); the KD,app is 
considerably less than that for wild-type, suggesting tighter binding. 
Surprisingly, p.A127G bound dicoumarol most tightly (Table 1; Fig. 3). On 
binding, the favourable interactions such as hydrogen bonds and van der 
Waal’s interactions between dicoumarol and p.A127G combined with any 
increase in entropy which occur (for example, in the solvent) must 
outweigh the unfavourable decrease in entropy for both p.A127G and 
dicoumarol. The overall Gibb’s free energy for dicoumarol binding to 
p.A127G must be more negative than that for dicoumarol binding to wild-
type and, surprisingly, p.N126A. Since dicoumarol was shown to be a poor 
inhibitor of the oxidoreductase activity of p.A127G, it can be assumed that 
the tight binding does not interfere directly with substrate binding and 
occur away from the active site.  
In the presence of 100 µM dicoumarol, wild-type and p.A127G retained 
most of their activity and p.N126A became almost inactive 
(Supplementary fig. S3). Dixon plot analysis showed that the inhibition is 
competitive with respect to NADPH (Data not shown). The change from 
asparagine to alanine allowed enhanced inhibition by dicoumarol, most 
likely by reduction of steric hindrance in the active site. Unlike NQO1, 
negative cooperativity towards dicoumarol was not observed in this 
dicoumarol accommodating variant (h =0.93 ±0.02; Table 1; Fig. 2).  
Both the dicoumarol-accommodating change and the change to increase 
flexibility were introduced simultaneously with the intention of 
investigating the effect on cooperativity towards dicoumarol. Dicoumarol 
also stabilised the p.N126A/A127G variant towards thermal denaturation 
with a slightly lower KD,app value than that for the p.N126A variant. In 
contrast, p.N126A/A127G has a much higher Ki,app value for dicoumarol 
than p.N126A (Table 1); therefore at a given concentration of dicoumarol 
more molecules of p.N126A are in complex with dicoumarol compared 
with p.N126A/A127G. KD,app values for dicoumarol binding to these two 
variants do not reflect this (Table 1); the Ki,app values are obtained 
kinetically and show that the inhibition of the double mutant is mixed 
while for p.N126A it is competitive. As expected, inhibition by dicoumarol 
occurs. However, the additional change to glycine has changed its nature 
from competitive to mixed (data not shown). Since this residue is in the 
active site, it is most likely that this change to glycine has increased the 
plasticity of the active site and allowed dicoumarol binding in different 
orientations. The Hill coefficient for dicoumarol is to the same as that for 
p.N126A. Therefore the increase in flexibility afforded by the additional 
change to glycine did not enable MdaB to exhibit negative cooperativity 
towards dicoumarol (Table 1; Fig. 2). 
 
Table 1 Kinetic and apparent binding constants for WT MdaB and variants 
Inhibitor WT p.A127G p.N126A p.N126A/A12
7G 
 kcat/Km /μM-1s-1 
None 0.23 ±0.02 1.00 ±0.17 0.007±0.00
1 
0.018 ±0.003 
     
 Kic,app/ mM 
Dicoumarol - - 2.8 ±1.2 23.8 ±7.0 
Nicotinamid
e 
218 ±4 Indeterminable - - 
NADP+ 0.7 ±0.4 2.3 ±0.0 - - 
  
 Kiu,app/ mM 
Nicotinamid
e 
1369±476 - - - 
NADP+ 14.6 ±6.2 14.3 ±6.4 - - 
     
 Hill Coefficient (h) 
Dicoumarol - - 0.93 ±0.02 0.93 ±0.02 
Nicotinamid
e 
1.20±0.12 1.40±0.12 - - 
NADP+ 0.74±0.07 0.71±0.05 - - 
NADPH 1.05±0.03 1.01±0.20 0.92±0.04 0.92±0.03 
     
 KD,app/mM 
Dicoumarol 0.526±0.2
07 
0.048±0.00
7 
0.151±0.03
1 
0.120±0.030 
Nicotinamid
e 
24 ±12 Destabilised - - 
NADP+ 8 ±1 No effect - - 
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Figure 2. (A) Steady state kinetics for WT MdaB and variants: the dependence of rate on NADPH concentration, rates were measured at 37 °C with 70 µM DCPIP (dimer 
concentrations:18 nM WT; 20 nM p.A127G; 500 nM p.N126A; 200 nM p.N126A/A127G). (B) Linear Hill plots constructed using the data in (A). For (A) and (B) each point 
represents the mean of three separate determinations and the error bar the standard deviation of the mean. (C) Inhibition by nicotinamide carried out at 70 µM NADPH and 70 
µM DCPIP (D) Inhibition by NADP+ carried out at 70 µM NADPH and 70 µM DCPIP (E) Inhibition by dicoumarol carried out at 150 µM NADPH and 70 µM DCPIP.  Linear Hill plots 
in (C), (D) and (E) were constructed to estimate the Hill coefficient for each inhibitor. Each point represents the mean of three separate determinations and the error bars show 
the standard deviation of this mean. This was repeated three times (one representative Hill plot shown corresponding to the median value for h).  
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Figure 3. Dependence of thermal stability on ligand concentration; Tm values determined from first derivative curves and plotted against the corresponding ligand 
concentration. Each point represents the mean of three separate determinations and the error bars were calculated from the standard deviations of these means.  Dicoumarol 
was dissolved in 0.13 M NaOH; the final concentration of NaOH in each reaction was constant at 0.65 mM. Nicotinamide and NADP+ were dissolved in Hepes-OH pH 7.3. 
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Conclusions 
MdaB has been characterized in terms of stability and oxidoreductase 
activity. Negative cooperativity and slight positive cooperativity towards 
NADP+ and nicotinamide respectively, occur in wild-type MdaB. The 
change from alanine to glycine did not change the cooperative behaviour 
of the enzyme. The reduction in steric hindrance afforded by the change 
from asparagine to alanine resulted in enhanced inhibition by dicoumarol. 
Dicoumarol did not induce negative cooperativity in this variant. The 
introduction of both changes simultaneously did not allow the enzyme to 
exhibit negative cooperativity towards dicoumarol. A communication 
pathway linking the active sites through changes in conformation and 
mobility has been computationally identified in human NQO1 [25]. 
Structural alignment of MdaB with human NQO1 indicates the presence of 
an equivalent structure in MdaB. However, there are no residues within 
this pathway which match those in the pathway in NQO1. Despite this, the 
bacterial enzyme exhibits negative cooperativity towards the product, 
NADP+. This suggests that the observed negative cooperativity 
propagates through a different pathway or that the communication occurs 
through the same connecting pathway as that in NQO1, but by a different 
mechanism.  MdaB’s ability to exhibit negative cooperativity towards 
NADP+ while also exhibiting Michaelis-Menten behaviour towards NADPH 
may have evolved to confer the ability to regulate homeostasis within the 
quinone cycles. Negative cooperativity in the inhibition by NADP+ allows 
for a greater sensitivity over a wider concentration range [33] and therefore 
tune the enzyme’s response to the supply of quinone from the reaction 
catalysed by QuMo. MdaB‘s tolerance to alteration of asparagine-127 to 
alanine in the active site suggests that additional changes to increase 
active site volumes would further broaden the range of molecules which 
bind to the enzyme.  This would be useful for the generation of variants of 
the enzyme for use in biocatalysis. 
Experimental Section 
Enzyme expression, purification and crosslinking: 
The coding sequence for MdaB was amplified by PCR using genomic DNA 
from E. coli HMS174(DE3) as template. The PCR product was inserted into 
the pET-46EK/LIC vector (Merck, UK) as described in the manufacturer’s 
instructions.  Site-directed mutagenesis using the QuikChange protocol [34] 
was used to make changes in the coding sequence.  Sequences were 
verified by DNA sequencing (GATC, London, UK;).  The vector inserts a 
sequence which codes for residues, MAHHHHHHVDDDDK at the 5’ end of 
the gene enabling purification of the recombinant proteins by Ni2+ 
chromatography (His-Select, Sigma, UK); expression and purification were 
carried out as previously described for budding yeast Lot6p [20].  Protein 
concentrations were estimated by the method of Bradford using BSA as a 
control [35]  Chemical crosslinking was carried out as previously described 
[20]. 
Enzyme kinetics 
MdaB activity was measured at 37 °C in either 50 mM phosphate buffer pH 
7.4 or 50 mM HEPES-OH buffer pH 7.33 using NADPH as the electron 
donor and DCPIP as the electron acceptor; lysozyme was included as a 
crowding agent (final concentration, 0.9 μM).  Initial rates were 
determined by measuring the rate of decrease in A600 resulting from the 
reduction of DCPIP.  Readings were taken every 5 s and all rates were 
obtained from the linear section at the beginning of each progress curve.  
All reactions were carried out in triplicate in 96-well plates.  Rates were 
measured at increasing concentrations of NADPH and a constant 
concentration of DCPIP (70 μM).  Corresponding background rates for the 
non-enzymatic reduction of DCPIP (70 μM) by NADPH at each 
concentration (at 37°C) were subtracted to give enzyme-catalysed rates.  
A calibration curve of A600 against [DCPIP] was constructed in triplicate (in 
both buffers) and the resulting equation of the line was used to determine 
εL in the Beer-Lambert equation (A=εLC) this was used to convert all rates 
from rate of change in A600 to rates in terms of change in [DCPIP].  The 
enzyme-catalysed rates were then divided by the [Enzyme]; the apparent 
Michaelis constant (Km,app) and turnover number (kcat,app) were determined 
from plots of enzyme-catalysed rate divided by [Enzyme] against the 
corresponding [NADPH].  The data were fitted to equation (1) using non-
linear curve fitting in GraphPad Prism 6.0 (GraphPad Software Inc. CA., 
USA). 
v/[E]=kcat,app[NADPH]/(Km,app+[NADPH])  (1) 
Where kcat,app is the apparent turnover number, Km,app is the apparent 
Michaelis constant and [E] is the concentration of enzyme. These data 
were also used to construct linearised Hill plots of -log10((v/[E]/kcat,app-
(v/[E]))) against log10([NADPH]) and a value for the Hill coefficient (the 
gradient) obtained [36]. 
Potential inhibitors (resveratrol, dicoumarol, AMP, NADP+, nicotinamide, 
folic acid, nicotinic acid and curcumin were tested. With the exception of 
nicotinamide and NADP+, none of these inhibited. Nicotinamide (0-300 
mM) and NADP+ (0-8 mM) were added into the reaction catalysed by WT 
MdaB and the variant p.A127G and their effect on the rate measured at 40 
μM and 70 μM NADPH and constant [DCPIP] (70 μM).  Dixon plots [37] were 
constructed for each concentration of NADPH and the apparent 
competitive inhibition constant (Kic,app) obtained as the intersection point 
of the lines.  [S]/v plots [38] were also constructed and where mixed 
inhibition was observed, the apparent uncompetitive inhibition constant 
(Kiu,app) determined as the intersection point of the lines.  Dicoumarol (0-
100 μM) was tested as an inhibitor of WT MdaB, p.A127G and p.N126A.  
Dicoumarol was dissolved in 0.13 M NaOH and the concentration of NaOH 
was constant (0.65 mM) in all reactions including those with zero 
dicoumarol. The initial rates of inhibited reactions were carried out at 
constant concentrations of DCPIP and NADPH (70 μM each) for WT MdaB 
and p.A127G.  Linearized Hill plots of -log10(v/(v0-v)) against -
log10[Inhibitor] (where v is the rate of the inhibited reaction and v0 is the 
uninhibited rate) were constructed; the Hill coefficient is the gradient of 
these plots. 
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Differential scanning fluorimetry 
Differential scanning fluorimetry was carried out as previously described 
[20]. An initial titration was carried out to identify an enzyme concentration 
which gave an optimum fluorescent signal.  Enzymes were diluted in 50 
mM HEPES, pH 7.33 to final concentrations in the range 0.25 μM to 5 μM 
dimer. This assay was also used to obtain apparent binding constants for 
inhibitors. The melting temperature of enzyme at each inhibitor 
concentration was plotted against the corresponding concentration of 
inhibitor and the data were fitted to equation (3) using non-linear curve 
fitting in GraphPad Prism.  
ΔTm= (ΔTm,max[Ligand])/(KD,app+[Ligand]) (3) 
Where ΔTm,max is the maximum, limiting change in Tm and KD,app is the 
apparent dissociation constant for ligand and protein. 
 
Supplementary Material 
Supporting information for this article is available on the WWW under 
http://dx.doi.org/10.1002/MS-number. 
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